Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merus NV (DE:2GH)
FRANKFURT:2GH
Holding DE:2GH?
Track your performance easily
2GH Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€18.60 - €58.50
Previous Close€48
Volume0.00
Average Volume (3M)82.00
Market Cap
€3.25B
Enterprise Value€2.54B
Total Cash (Recent Filing)$787.42M
Total Debt (Recent Filing)$11.02M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Oct 30, 2024EPS Estimate
-€0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding68,210,479
10 Day Avg. Volume10
30 Day Avg. Volume82
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.29
Price to Sales (P/S)100.28
Price to Cash Flow (P/CF)156.60
P/FCF Ratio212.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue72.07
Enterprise Value/Gross Profit57.71
Enterprise Value/Ebitda-29.93
Forecast
1Y Price Target
€81.68Price Target Upside70.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Merus News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMRUS announced that its Phase 3 LiGeR-HN1 trial in frontline PD-L1+ head & neck squamous cell carcinoma (HNSCC) had dosed its first patient.
EfficacyPetosemtamab demonstrated a 65% confirmed Overall Response Rate (ORR) in the same setting.
Strategic PartnershipsThe company is seeking strategic partnerships for the program.
Bears Say
Adverse EventsBCA101 showed one grade 3 tracheal hemorrhage at ESMO in 2023, and we look for any updates on bleeding events.
Clinical DataBicara's updated Phase 1/1b data for BCA101 seem weaker vs Merus' MCLA-158 on Overall Response Rate (ORR).
Patient OutcomesData looked weaker in HPV+ patients, which will be excluded from their pivotal trial.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.46% Insiders
18.75% Mutual Funds
0.05% Other Institutional Investors
78.96% Public Companies and
Individual Investors
2GH FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was €18.60 and its highest was €58.50 in the past 12 months.
What is Merus NV’s market cap?
Currently, no data Available
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is Oct 30, 2024 which is in 11 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Aug 01, 2024. The company reported -€0.74 earnings per share for the quarter, missing the consensus estimate of -€0.693 by -€0.047.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -€0.8.
How many shares outstanding does Merus NV have?
Merus NV has 68,210,480 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -€0.74 in its last earnings report, missing expectations of -€0.693. Following the earnings report the stock price went down -4.508%.
Which hedge fund is a major shareholder of Merus NV?
Among the largest hedge funds holding Merus NV’s share is Deerfield Management Company, LP. It holds Merus NV’s shares valued at 163M.
---
Merus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€81.68 (70.17% Upside)
€81.68 (70.17% Upside)
Blogger Sentiment
Bullish
DE:2GH Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $270.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.36%
12-Months-Change
Fundamentals
Return on Equity
-33.39%
Trailing 12-Months
Asset Growth
145.37%
Trailing 12-Months
Company Description
Merus NV
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
---
2GH Stock 12 Month Forecast
Average Price Target
€81.68
▲(70.17% Upside)
Technical Analysis
Merus
―
ALX Oncology Holdings
―
Mersana Therapeutics
―
Blueprint Medicines
―
RAPT Therapeutics
―
Best Analysts Covering 2GH
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+53.17%
reiterated a buy rating 20 days ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +53.17% per trade.
---